

Fredrik Bergh ThorÃ©n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8218777/publications.pdf>

Version: 2024-02-01

60
papers

1,595
citations

257450

24
h-index

315739

38
g-index

64
all docs

64
docs citations

64
times ranked

2138
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of IL-1 β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. <i>OncImmunity</i> , 2021, 10, 1944538.	4.6	11
2	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 796072.	4.8	2
3	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 109-111.	3.3	13
4	Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e49-e53.	2.5	4
5	Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species. <i>Cancer Immunology Research</i> , 2020, 8, 1532-1541.	3.4	10
6	miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 119.	3.7	26
7	Downregulation of HLA Class I Renders Inflammatory Neutrophils More Susceptible to NK Cell-Induced Apoptosis. <i>Frontiers in Immunology</i> , 2019, 10, 2444.	4.8	12
8	Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. <i>Leukemia and Lymphoma</i> , 2019, 60, 2771-2778.	1.3	15
9	The HLA-B \ast 21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. <i>Blood</i> , 2019, 133, 1479-1488.	1.4	50
10	Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1318-1318.	1.4	0
11	Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells. <i>Neoplasia</i> , 2018, 20, 25-31.	5.3	9
12	Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. <i>Frontiers in Oncology</i> , 2018, 8, 218.	2.8	25
13	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. <i>Cancer Immunology Research</i> , 2018, 6, 1110-1119.	3.4	8
14	Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia. <i>Journal of Leukocyte Biology</i> , 2017, 102, 467-474.	3.3	17
15	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 2552-2559.	7.2	16
16	NOX2-dependent immunosuppression in chronic myelomonocytic leukemia. <i>Journal of Leukocyte Biology</i> , 2017, 102, 459-466.	3.3	21
17	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1473-1484.	4.2	45
18	The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands. <i>Frontiers in Immunology</i> , 2017, 8, 510.	4.8	29

#	ARTICLE	IF	CITATIONS
19	Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha " can tumor immune escape after immunotherapy accelerate disease progression?. <i>Oncolmmunology</i> , 2016, 5, e1091147.	4.6	12
20	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. <i>Oncolmmunology</i> , 2016, 5, e1041701.	4.6	34
21	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 7586-7596.	1.8	13
22	Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells. <i>Oncotarget</i> , 2016, 7, 32046-32053.	1.8	37
23	Abstract CT116: Dynamics of cytotoxic T-cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. , 2016, ,		0
24	Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase. <i>Journal of Immunology</i> , 2015, 194, 5014-5021.	0.8	38
25	TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses. <i>Journal of Immunology</i> , 2015, 195, 1121-1128.	0.8	48
26	Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 favors sustained lymphocyte recovery in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2015, 94, 279-280.	2.2	5
27	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. <i>Oncotarget</i> , 2015, 6, 42569-42574.	1.8	35
28	Role of the ERK Pathway for Oxidant-Induced Parthanatos in Human Lymphocytes. <i>PLoS ONE</i> , 2014, 9, e89646.	2.5	31
29	CD20 antibodies induce production and release of reactive oxygen species by neutrophils. <i>Blood</i> , 2014, 123, 4001-4002.	1.4	11
30	Abstract 2545: Histamine dihydrochloride and interleukin-2 for relapse prevention in AML: Initial results of the Re:MISSION phase IV trial. <i>Cancer Research</i> , 2014, 74, 2545-2545.	0.9	1
31	Reactive Oxygen Species Produced By Myeloid Cells Block CD20-Antibody Dependent NK Cell-Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 3638-3638.	1.4	0
32	Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2. <i>Blood</i> , 2014, 124, 3680-3680.	1.4	0
33	Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes. <i>Journal of Leukocyte Biology</i> , 2013, 93, 155-160.	3.3	14
34	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. <i>Blood Reviews</i> , 2013, 27, 209-216.	5.7	71
35	A simple skin blister technique for the study of in vivo transmigration of human leukocytes. <i>Journal of Immunological Methods</i> , 2013, 393, 8-17.	1.4	19
36	Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1547-1551.	4.2	20

#	ARTICLE	IF	CITATIONS
37	Abstract B66: Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent cell death in natural killer cells.. , 2013, , .		0
38	Human NK Cells Induce Neutrophil Apoptosis via an NKp46- and Fas-Dependent Mechanism. Journal of Immunology, 2012, 188, 1668-1674.	0.8	96
39	Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood, 2012, 119, 5832-5837.	1.4	75
40	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica, 2012, 97, 1904-1908.	3.5	44
41	Analyzing Cell Death Events in Cultured Leukocytes. Methods in Molecular Biology, 2012, 844, 65-86.	0.9	20
42	Abstract 5414: Malignant monocytic AML cells trigger apoptosis in anti-leukemic lymphocytes: Role of NADPH oxidase gp91phoxexpression and PARP-1 activity. , 2012, , .		0
43	Antitumor properties of histamine in vivo. Nature Medicine, 2011, 17, 537-537.	30.7	13
44	Adjuvant interferon: extended follow-up times needed?. Lancet Oncology, The, 2011, 12, 419.	10.7	2
45	Redox Remodeling by Dendritic Cells Protects Antigen-Specific T Cells against Oxidative Stress. Journal of Immunology, 2011, 187, 6243-6248.	0.8	20
46	Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Review of Hematology, 2010, 3, 381-391.	2.2	44
47	The anionic amphiphile SDS is an antagonist for the human neutrophil formyl peptide receptor 1. Biochemical Pharmacology, 2010, 80, 389-395.	4.4	7
48	Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opinion on Biological Therapy, 2009, 9, 1217-1223.	3.1	23
49	Postâ€consolidation Immunotherapy with Histamine Dihydrochloride and Interleukinâ€2 in AML. Scandinavian Journal of Immunology, 2009, 70, 194-205.	2.7	48
50	Cutting Edge: Antioxidative Properties of Myeloid Dendritic Cells: Protection of T Cells and NK Cells from Oxygen Radical-Induced Inactivation and Apoptosis. Journal of Immunology, 2007, 179, 21-25.	0.8	56
51	P-06 Long term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomized multicentre trial. Melanoma Research, 2007, 17, A19.	1.2	0
52	The CD16â~/CD56bright Subset of NK Cells Is Resistant to Oxidant-Induced Cell Death. Journal of Immunology, 2007, 179, 781-785.	0.8	55
53	Histamine Dihydrochloride Maintains Cytotoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress.. Blood, 2007, 110, 2309-2309.	1.4	13
54	Changes in Activation States of Murine Polymorphonuclear Leukocytes (PMN) during Inflammation: a Comparison of Bone Marrow and Peritoneal Exudate PMN. Vaccine Journal, 2006, 13, 575-583.	3.1	55

#	ARTICLE	IF	CITATIONS
55	NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. <i>British Journal of Haematology</i> , 2006, 132, 91-98.	2.5	80
56	Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. <i>Acta Oncologica</i> , 2006, 45, 389-399.	1.8	35
57	Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes. <i>Journal of Immunology</i> , 2006, 176, 7301-7307.	0.8	51
58	A Proinflammatory Peptide from Herpes Simplex Virus Type 2 Glycoprotein G Affects Neutrophil, Monocyte, and NK Cell Functions. <i>Journal of Immunology</i> , 2005, 174, 2235-2241.	0.8	53
59	Activation of cytotoxic lymphocytes by interferon- γ : role of oxygen radical-producing mononuclear phagocytes. <i>Journal of Leukocyte Biology</i> , 2004, 76, 1207-1213.	3.3	21
60	A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. <i>Journal of Leukocyte Biology</i> , 2004, 76, 1180-1186.	3.3	81